Mengzhao Wang, Yun Fan, Meili Sun, Yongsheng Wang, Yanqiu Zhao, Bo Jin, Ying Hu, Zhigang Han, Xia Song, Anwen Liu, Kejing Tang, Cuimin Ding, Li Liang, Lin Wu, Junzhen Gao, Jianghong Wang, Ying Cheng, Jianying Zhou, Yong He, Xiaorong Dong, Yu Yao, Yan Yu, Huijie Wang, Si Sun, Jianan Huang, Jian Fang, Wen Li, Lin Wang, Xiubao Ren, Chengzhi Zhou, Yanping Hu, Dahai Zhao, Runxiang Yang, Fei Xu, Yijiang Huang, Yueyin Pan, Jiuwei Cui, Yan Xu, Zhenfan Yang, Yuankai Shi
BACKGROUND: Sunvozertinib is an oral, irreversible, and selective tyrosine kinase inhibitor that has a favourable safety profile and encouraging antitumour activity, as shown in phase 1 studies of patients with heavily pretreated non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation (exon20ins). We aimed to assess the antitumour efficacy of sunvozertinib in patients with platinum-pretreated locally advanced or metastatic NSCLC with EGFR exon20ins. METHODS: WU-KONG6 is a single-group, open-label, multicentre phase 2 trial of sunvozertinib monotherapy, conducted across 37 medical centres in China...
March 2024: Lancet Respiratory Medicine